drugset / Trial / NCT03446976

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

NCT03446976

Phase 1 Completed 218 enrolled Celltrion
RandomizedParallel-groupOpen-labelOther

Summary

This study compares two administration methods of CT-P13. Half of participants will receive CT-P13 by pre-filled syringe while the other half will receive CT-P13 by auto-injector.

Timeline

Start
2018-02-21
Primary completion
2018-07-26
Completion
2018-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody Subcutaneous

Indications

No indication recorded.